Stay updated on Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision: v3.4.3 updates the site's version label. No visible changes to study details or patient-facing information.
    Difference
    0.0%
    Check dated 2026-03-11T15:14:53.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the prior operating-status notice (Revision: v3.4.1). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T05:55:35.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a site-wide notice about government funding affecting updates and the NIH Clinical Center's status. The page revision was updated from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T04:28:51.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    A new 'Show glossary' toggle is added, along with footer metadata showing 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0'. The deletions remove older wording/variants ('Last Update Submitted that met QC Criteria', 'No FEAR Act data', 'Revision: v3.3.4'), reflecting a minor UI update and data-label cleanup. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T02:08:10.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Revision: v3.3.4 was added and Revision: v3.3.3 was removed; no study details, enrollment, or eligibility information appear to be changed; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T01:25:21.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    A Locations section with a Washington entry has been added, improving visibility of where the study is conducted. The previous 'Washington Locations' entry and the HHS Vulnerability Disclosure have been removed.
    Difference
    0.2%
    Check dated 2025-12-23T08:14:57.000Z thumbnail image

Stay in the know with updates to Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.